Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw material production, indicating a steady increase in output and providing insights into future market dynamics [1] Industry Summary - As of December 2025, China's chemical pharmaceutical raw material production reached 361,000 tons, reflecting a year-on-year growth of 2.3% [1] - The cumulative production of chemical pharmaceutical raw materials for the entire year of 2025 was 3,707,000 tons, showing a cumulative growth of 1.6% [1] - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry research institution in China [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1] - The report provides a comprehensive analysis of the market supply and demand situation in the chemical pharmaceutical industry from 2026 to 2032, offering insights for investment decisions [1]

Core Viewpoint - The company has received a production license for a new manufacturing site, which will enhance its production capacity and efficiency for a specific product, although it will not significantly impact current performance [1] Group 1: Company Announcement - Baiyunshan's subsidiary, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd., has been granted a production license by the Guangdong Provincial Drug Administration [1] - The license allows Qixing Pharmaceutical to commission Baiyunshan Pharmaceutical General Factory to produce a new version of the product "Xuhuanting Granules" (sugar-free) at an additional manufacturing location [1] Group 2: Operational Impact - The addition of a new production site is expected to increase production capacity and improve efficiency to meet market demand [1] - The impact of this license on the company's current financial performance is stated to be negligible [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於廣州廣藥廣開創業投資基金合夥企業（有限合伙）完成私募基金備案暨關聯交易進展的公 告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2026年2月2日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2026-001 广州白云山医药集团股份有限公司 资合伙企业（有限合伙）（"广药二期基金"）与广州广药资本私募基金管理有 限公司（"广药资本"）、广州开发区投资基金管理有限公司（"广开基金"） 合作设立广 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司藥品生產許可證變更的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2026年2月2日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广州白云山奇星药业有限公司（以下简称" ...

近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 子公司广州白云山奇星药业有限公司（以下简称"奇星药业"）收 到广东省药品监督管理局核准签发的《药品生产许可证》，同意奇 星药业委托广州白云山医药集团股份有限公司白云山制药总（以下 简称"白云山制药总厂"）厂生产虚汗停颗粒（无糖型）在原委托 生产地址基础上，新增受托生产地址。现将相关情况公告如下： 一、《药品生产许可证》基本情况 企业名称：广州白云山奇星药业有限公司 证券代码：600332 证券简称：白云山 公告编号：2026-002 广州白云山医药集团股份有限公司 关于子公司《药品生产许可证》变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 同意奇星药业在原批准信息"委托广州白云山医药集团股份有 限公司白云山制药总厂生产虚汗停颗粒（无糖型）（国药准字 Z20093240），委托生产地址：广东省揭西县环城东路 36 号（制剂）、 广州市番禺区南村镇七星岗（提取），委托生产车间：第三制造部 普通口服固体制剂车间、南村提取车间，颗粒剂委托生产线：颗粒 剂生产线、中 ...

证券代码：600332 证券简称：白云山 公告编号：2026-001 广州白云山医药集团股份有限公司 关于广州广药广开创业投资基金合伙企业（有限合伙） 完成私募基金备案暨关联交易进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | 广州广药广开创业投资基金合伙企业（有限合伙） | | | | --- | --- | --- | --- | | 投资金额（万元） | 9,750 | | | | 投资进展阶段 | 完成 进展 | 终止 | 交易要素变更 | | | 广州广药广开创业投资基金合伙企业（有限合伙）存在 | | | | 特别风险提示 | 未能寻求到合适投资标的的风险；因决策失误或行业环 | | | | | 境发生重大变化，导致基金收益未达预期的风险。 | | | 一、合作投资基本概述情况 2025 年 12 月 22 日，广州白云山医药集团股份有限公司（"本公司"）召 开第九届董事会第三十二次会议，审议通过了《关于广州广药二期基金股权投资 合伙企业（有限合伙）认购广州广 ...

白云山公告称，附属企业广药二期基金与广药资本、广开基金合作设立广药广开基金，投资9750万元。 该基金于2026年1月8日完成工商登记，各合伙人实缴首期出资1.2亿元，1月30日在中国证券投资基金业 协会完成备案。本次投资符合广药二期基金投资方向，利于扩大规模、分散风险等。截至目前，公司与 私募基金合作投资合计5.87亿元。 ...

Core Viewpoint - The recent performance of the Chinese medicine sector, particularly the Chinese Medicine ETF (560080), indicates a potential shift in investment style, with increasing capital inflow and favorable valuation metrics suggesting a recovery phase ahead for the industry [3][8]. Group 1: Market Performance - On February 2, the Shanghai Composite Index fell by 2.48%, while the Chinese Medicine ETF (560080) experienced a decline of 1.24%, with a total trading volume exceeding 70 million yuan [1]. - The Chinese Medicine ETF has seen continuous capital inflow, accumulating over 100 million yuan in net inflow over the past five days [1][3]. Group 2: Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the Chinese Medicine ETF is 23.96, indicating that the valuation is below 85.61% of the time since its inception in May 2015, highlighting attractive valuation opportunities [3]. - The Chinese medicine sector is perceived to be entering a "sweet spot" in terms of valuation, with a significant portion of stocks showing potential for recovery [3]. Group 3: Individual Stock Performance - Most of the weighted stocks in the Chinese Medicine ETF index closed lower, with notable declines including Jilin Aodong down over 7% and Darentang down over 3% [5]. - Conversely, Dong'e Ejiao was one of the few stocks that rose, gaining over 1% [5]. Group 4: Earnings Forecasts - Jilin Aodong has projected a net profit of approximately 2.265 to 2.482 billion yuan for 2025, representing a year-on-year growth of 46.0% to 60.0%, attributed to increased fair value changes and investment income [7]. - As of January 31, 11 companies within the Chinese Medicine ETF index have released earnings forecasts, with six reporting positive year-on-year growth [7]. Group 5: Future Outlook - The Chinese medicine sector is expected to experience a rebound in 2026, driven by inventory digestion and an anticipated increase in flu incidence in Q4 2025, which may enhance sales of related OTC products [8]. - The potential update of the essential drug catalog is also seen as a catalyst for growth, with companies that can meet the new criteria likely to benefit [8]. Group 6: Investment Themes - Three main investment themes have been identified for the Chinese medicine industry: price governance, consumption recovery, and state-owned enterprise reform [9][10][11]. - The focus on price governance suggests that companies with competitive advantages may benefit from price reductions leading to increased market share [9]. - The recovery of consumer demand, driven by macroeconomic improvement and an aging population, is expected to support sales growth in the Chinese medicine sector [10]. - State-owned enterprises in the industry are anticipated to present investment opportunities as reforms aim to enhance efficiency and performance [11].

Group 1 - The event "Unveiling the Banner and Leading the Integration of National and Private Enterprises" aims to enhance cooperation between state-owned and private enterprises in Guangzhou, aligning with the city's economic goals for 2026 [1][3] - The initiative focuses on 12 key projects from 10 major state-owned enterprises, facilitating direct communication and collaboration with private enterprises in sectors such as biomedicine, high-end equipment manufacturing, construction technology, and artificial intelligence [1][2] - The event serves as a platform for mutual empowerment between state-owned and private economies, promoting a collaborative ecosystem where state-owned enterprises provide structure while private enterprises contribute innovation [2][3] Group 2 - Private enterprises like Guangzhou Lido Robot Intelligent Technology Group and Guangdong Yushun Digital Technology showcased customized solutions, demonstrating their technological capabilities and practical applications in response to state-owned enterprises' needs [2] - The event included a free exchange segment where representatives from both sectors engaged in detailed discussions, fostering a consensus for collaboration and enhancing the integration of resources [2] - The organizers plan to establish a long-term mechanism for "demand release - precise matching - project implementation - follow-up service" to ensure continuous and effective cooperation between state-owned and private enterprises [2][3]

十大招股说明书翻译公司排行榜公开，领先者备受瞩目 招股说明书是企业上市过程中的核心法律文件，其翻译不仅要求极高的语言准确性，更涉及金融、法 律、行业技术等多领域的专业表述，任何细微偏差都可能影响信息披露的合规性与投资者的决策。面对 术语严谨、格式规范、时效性强等难点，选择一家专业、可靠的翻译服务商至关重要。 近日，业内权威评选的"十大招股说明书翻译公司"榜单揭晓，信实翻译公司凭借其卓越的综合实力与众 多标杆案例成功入选，成为备受市场瞩目的领先者之一。 权威资质铸就专业基石 信实翻译公司作为全国大型综合性翻译公司，其专业地位获得多方权威认可：不仅是中国翻译协会理事 单位、广东翻译协会会员单位，更是广州翻译协会常务副会长单位（此职务在业内具有唯一性，彰显其 领导地位）。同时，公司也是中国华南英国商会（原广东英国商会）/British Chamber of Commerce South China会员单位（该身份稀缺，深度链接国际商务资源），以及深圳市跨境电子商务协会会员单 位。 公司恪守国际最高标准，独家集齐三大ISO国际权威认证：ISO9001质量管理体系认证、ISO17100翻译 服务体系认证以及ISO270 ...